- Home
- CBNK vs ALT Comparison
CBNK vs ALT Comparison
Compare CBNK & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBNK | ALT |
|---|---|---|
| Founded | 1974 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.4M | 415.3M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | CBNK | ALT |
|---|---|---|
| Price | $31.50 | $4.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $34.50 | $16.00 |
| AVG Volume (30 Days) | 40.2K | ★ 5.3M |
| Earning Date | 01-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | ★ 60.85 | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | ★ $230,026,000.00 | $20,000.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $8.57 | N/A |
| P/E Ratio | $9.45 | ★ N/A |
| Revenue Growth | ★ 34.78 | N/A |
| 52 Week Low | $24.69 | $2.90 |
| 52 Week High | $36.40 | $7.73 |
Technical Indicators
Market Signals| Indicator | CBNK | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 68.23 | 50.37 |
| Support Level | $29.05 | $5.19 |
| Resistance Level | $32.94 | $5.75 |
| Average True Range (ATR) | 0.98 | 0.57 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 73.89 | 36.31 |
Price Performance
Historical ComparisonAbout CBNK Capital Bancorp Inc.
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.